GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
GILEAD SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$153.07−3.12 (-2.00%)
Close on Oct 19, 2026
- Market cap
- $190.27B
- P/E (TTM)
- –
- Dividend yield
- 2.06%
GILEAD SCIENCES, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $7.63B | $6.95B | $7.90B | $7.35B | $7.05B | $6.61B | $7.54B | $7.52B | $6.91B | $6.65B | $7.07B | $6.99B | 97.7% | +8.1% |
| Total HIV | $5.69B | $5.03B | $5.80B | $5.28B | $5.09B | $4.59B | $5.45B | $5.07B | $4.75B | $4.34B | $4.69B | $4.67B | 73.0% | +11.9% |
| Biktarvy | $3.77B | $3.36B | $3.97B | $3.69B | $3.53B | $3.15B | $3.77B | $3.47B | $3.23B | $2.95B | $3.11B | $3.09B | 48.3% | +6.9% |
| Descovy | $967.00M | $807.00M | $819.00M | $701.00M | $653.00M | $586.00M | $617.00M | $586.00M | $485.00M | $426.00M | $510.00M | $511.00M | 12.4% | +48.1% |
| Total Liver Disease | $877.00M | $767.00M | $845.00M | $819.00M | $795.00M | $758.00M | $719.00M | $733.00M | $832.00M | $737.00M | $691.00M | $706.00M | 11.2% | +10.3% |
| Total Oncology | $873.00M | $810.00M | $841.00M | $788.00M | $849.00M | $757.00M | $843.00M | $816.00M | $841.00M | $789.00M | $765.00M | $769.00M | 11.2% | +2.8% |
| Trodelvy | $457.00M | $402.00M | $384.00M | $357.00M | $364.00M | $293.00M | $355.00M | $332.00M | $320.00M | $309.00M | $299.00M | $283.00M | 5.9% | +25.5% |
| Total Cell Therapy | $417.00M | $407.00M | $458.00M | $432.00M | $485.00M | $464.00M | $488.00M | $485.00M | $521.00M | $480.00M | $467.00M | $486.00M | 5.3% | -14.0% |
| Yescarta | $346.00M | $332.00M | $368.00M | $349.00M | $393.00M | $386.00M | $389.00M | $387.00M | $414.00M | $380.00M | – | – | 4.4% | -12.0% |
| Sofosbuvir/Velpatasvir | $303.00M | $283.00M | $276.00M | $309.00M | $342.00M | $346.00M | $330.00M | $385.00M | $476.00M | $405.00M | $378.00M | $377.00M | 3.9% | -11.4% |
| Genvoya | $289.00M | $264.00M | $380.00M | $377.00M | $377.00M | $364.00M | $470.00M | $449.00M | $440.00M | $403.00M | $516.00M | $503.00M | 3.7% | -23.3% |
| Vemlidy | $289.00M | $237.00M | $287.00M | $280.00M | $252.00M | $252.00M | $260.00M | $232.00M | $243.00M | $225.00M | $217.00M | $228.00M | 3.7% | +14.7% |
| Odefsey | $239.00M | $221.00M | $310.00M | $277.00M | $298.00M | $281.00M | $336.00M | $326.00M | $315.00M | $310.00M | $339.00M | $343.00M | 3.1% | -19.8% |
| Yeztugo | $232.00M | $166.00M | – | – | $15.00M | $0 | – | – | – | – | – | – | 3.0% | +1446.7% |
| Royalty, contract and other revenues | $176.00M | $14.00M | $22.00M | $424.00M | $27.00M | $54.00M | $33.00M | $30.00M | $41.00M | $39.00M | $44.00M | $56.00M | 2.3% | +551.9% |
| Livdelzi | $167.00M | $133.00M | – | – | $78.00M | $40.00M | – | – | – | – | – | – | 2.1% | +114.1% |
| Total Other | $161.00M | $196.00M | $205.00M | $184.00M | $202.00M | $209.00M | $184.00M | $201.00M | $280.00M | $224.00M | $201.00M | $216.00M | 2.1% | -20.3% |
| Symtuza - Revenue share | $138.00M | $138.00M | $133.00M | $124.00M | $124.00M | $114.00M | $144.00M | $139.00M | $168.00M | $141.00M | – | – | 1.8% | +11.3% |
| Other Liver Disease | $118.00M | $114.00M | $281.00M | $231.00M | $123.00M | $121.00M | $130.00M | $116.00M | $113.00M | $107.00M | $96.00M | $102.00M | 1.5% | -4.1% |
| AmBisome | $110.00M | $138.00M | $118.00M | $123.00M | $129.00M | $139.00M | $109.00M | $130.00M | $151.00M | $144.00M | $111.00M | $115.00M | 1.4% | -14.7% |
| Tecartus | $70.00M | $75.00M | $90.00M | $83.00M | $92.00M | $78.00M | $98.00M | $98.00M | $107.00M | $100.00M | $98.00M | $96.00M | 0.9% | -23.9% |
| Other HIV | $56.00M | $73.00M | $190.00M | $112.00M | $92.00M | $91.00M | $112.00M | $100.00M | $105.00M | $117.00M | $80.00M | $94.00M | 0.7% | -39.1% |
| Other | $51.00M | $58.00M | $86.00M | $61.00M | $73.00M | $70.00M | $75.00M | $71.00M | $130.00M | $80.00M | $90.00M | $101.00M | 0.7% | -30.1% |
| Veklury | $23.00M | $144.00M | $211.00M | $277.00M | $121.00M | $302.00M | $338.00M | $692.00M | $214.00M | $555.00M | $719.00M | $636.00M | 0.3% | -81.0% |
| Letairis | – | – | – | – | – | – | – | – | – | – | $36.00M | $36.00M | – | – |
| Other HIV | – | – | – | – | – | – | – | – | – | – | $15.00M | $13.00M | – | – |
| Revenue share - Symtuza | – | – | – | – | – | – | – | – | – | – | $139.00M | $131.00M | – | – |
| Complera/Eviplera | – | – | – | – | – | – | – | – | – | – | $25.00M | $34.00M | – | – |
| Stribild | – | – | – | – | – | – | – | – | – | – | $22.00M | $25.00M | – | – |
| Truvada | – | – | – | – | – | – | – | – | – | – | $17.00M | $22.00M | – | – |
| Ledipasvir/Sofosbuvir | – | – | – | – | – | – | – | – | – | – | $16.00M | $23.00M | – | – |
| Sofosbuvir/Velpatasvir | – | – | – | – | – | – | – | – | – | – | $378.00M | $377.00M | – | – |
| Total HCV | – | – | – | – | – | – | – | – | – | – | $432.00M | $438.00M | – | – |
| Vemlidy | – | – | – | – | – | – | – | – | – | – | $217.00M | $228.00M | – | – |
| Other HB/HDV | – | – | – | – | – | – | – | – | – | – | $21.00M | $20.00M | – | – |
| Total HBV/HDV | – | – | – | – | – | – | – | – | – | – | $259.00M | $269.00M | – | – |
| Other HCV | – | – | – | – | – | – | – | – | – | – | – | $38.00M | – | – |
| Yescarta | – | – | – | – | – | – | – | $387.00M | $414.00M | $380.00M | – | $391.00M | – | – |
| Viread | – | – | – | – | – | – | – | – | – | – | $21.00M | $21.00M | – | – |
| Symtuza - Revenue share | – | – | – | – | – | – | – | $139.00M | $168.00M | $141.00M | – | $131.00M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $5.60B | $4.93B | $5.88B | $5.28B | $5.05B | $4.67B | $5.57B | $5.45B | $4.94B | $4.63B | $5.19B | $5.02B | 71.8% | +10.9% |
| Europe | $1.32B | $1.14B | $1.24B | $1.56B | $1.19B | $1.08B | $1.18B | $1.17B | $1.13B | $1.16B | $1.16B | $1.04B | 17.0% | +11.4% |
| Rest of World | $876.00M | $889.00M | $813.00M | $933.00M | $842.00M | $915.00M | $826.00M | $929.00M | $879.00M | $894.00M | $765.00M | $993.00M | 11.2% | +4.0% |
| Rest of World | – | – | – | – | – | – | – | – | – | $894.00M | $765.00M | $993.00M | – | – |
From the segment and revenue-disaggregation notes of Gilead Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.